Bristol Myers Squibb Company $BMY Stock Position Decreased by Lantern Wealth Advisors LLC

Lantern Wealth Advisors LLC reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 57.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,376 shares of the biopharmaceutical company’s stock after selling 9,894 shares during the period. Lantern Wealth Advisors LLC’s holdings in Bristol Myers Squibb were worth $460,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Altura Wealth Advisors Inc. increased its position in shares of Bristol Myers Squibb by 1.2% in the third quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock valued at $856,000 after buying an additional 161 shares in the last quarter. Barrett & Company Inc. raised its stake in shares of Bristol Myers Squibb by 9.2% during the 3rd quarter. Barrett & Company Inc. now owns 5,999 shares of the biopharmaceutical company’s stock worth $374,000 after buying an additional 506 shares during the last quarter. Capital City Trust Co. FL boosted its position in shares of Bristol Myers Squibb by 0.7% in the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock worth $1,455,000 after buying an additional 167 shares in the last quarter. Sterling Capital Management LLC boosted its position in shares of Bristol Myers Squibb by 4.3% in the 3rd quarter. Sterling Capital Management LLC now owns 229,996 shares of the biopharmaceutical company’s stock worth $14,352,000 after buying an additional 9,542 shares in the last quarter. Finally, XXI Wealth LLC grew its stake in Bristol Myers Squibb by 87.4% in the 3rd quarter. XXI Wealth LLC now owns 30,096 shares of the biopharmaceutical company’s stock valued at $1,878,000 after acquiring an additional 14,039 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.05% of the stock is owned by corporate insiders.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
• Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
• Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
• Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
• Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Bank of America dropped their target price on shares of Bristol Myers Squibb from $71.00 to $66.00 in a report on Friday, October 9th. Daiwa Securities Group upped their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Jefferies Financial Group reiterated a “buy” rating and issued a $76.00 price target on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Finally, Roth Capital assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $64.88.

Bristol Myers Squibb Stock Down 2.3%

Shares of NYSE:BMY opened at $61.58 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The stock’s fifty day simple moving average is $63.26 and its 200-day simple moving average is $60.33. The company has a market capitalization of $125.79 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.51 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.